Skip to main content
ALEC logo

ALEC · Alector, Inc.

Track ALEC — free
$2.34 +0.04 (+1.52%) At close · Nov 20
Market Cap
$347.63M
Shares
148.88M
Volume · Nov 20 1.95M Avg daily vol (3M) 3.3M

Price & Indicators

 

Key stats

Close
$2.34
Fri 20 Nov
Open
$2.28
Fri 20 Nov
Average volume, 30 days
2.1M
shares a session
Short interest
8.4M
5.6% of shares · 3.6 days to cover
Day range
$2.27$2.48
Open $2.28 Close $2.34
52-week closing range
$1.14$2.72
Close $2.34 14.2% under the high
Short volume, last session
54%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 5
Price history
Jan 2020 to Nov 2026

Up next

May 7, 2027 Est · unconfirmed · in 24 wks

Latest documents

2026
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Genentech licenses AL050 for $100.0 million upfront

Alector licensed AL050 to Genentech for a $100.0 million upfront payment and up to $1.17 billion in milestones, plus tiered royalties. The company expects current liquidity to fund operations into the second half of 2029.

Revenue $162.87M ▲ 4895.9% Net income $124.6M Diluted EPS $1.11
Read from the MD&A section
4 source passages
AL050 combines an Alector-engineered GCase, optimized for greater enzymatic activity and a longer half-life, with ABC, which is designed to transport therapeutics across the blood-brain barrier (BBB). On September 30, 2026, we entered into a License Agreement (Genentech License Agreement) with Genentech, Inc. (Genentech), under which we granted Genentech exclusive worldwide rights to develop and commercialize our AL050 program. Under the Genentech License Agreement, the Company received a $100.0 million upfront payment subsequent to September 30, 2026, and are eligible to receive up to an additional $1.17 billion in development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales of products from the AL050 program at rates ranging from single-digit to double-digit percentages. Based on our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities, together with the upfront payment received subsequent to September 30, 2026, under the Genentech License Agreement, net of the payment made under the Spur Agreement, and the net proceeds from the October 2026 underwritten offering, will enable us to fund our operations and capital expenditure requirements into the second half of 2029. Open the document at this passage
Nov 5
Current report 8-K
Genentech licenses AL050 for $100 million upfront

Alector licensed AL050 globally to Genentech, receiving $100 million upfront and eligibility for up to $1.17 billion in milestones. Third-quarter net income was $124.6 million, and cash, cash equivalents and investments totaled $138.7 million at September 30, 2026.

Financial results
4 source passages
Alector entered into an exclusive global license agreement with Genentech, a member of the Roche Group, granting Genentech worldwide rights to develop and commercialize Alector’s AL050 program, our brain-penetrant engineered glucocerebrosidase (GCase) ERT. Under the agreement, Alector has received a $100 million upfront payment and is eligible to receive up to an additional $1.17 billion in development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales. For the quarter ended September 30, 2026, Alector reported a net income of $124.6 million, or $1.11 net income per share, compared to a net loss of $ 34.7 million, or $0.34 net loss per share, for the same period in 2025. Cash, cash equivalents, and investments were $138.7 million as of September 30, 2026. Open the document at this passage
Oct 16
Current report 8-K Events of Oct 15
Entered into a material agreement, Other events

Alector entered an underwriting agreement with Morgan Stanley & Co. LLC and BTIG, LLC for 36,600,000 shares at $2.05 per share, expecting gross proceeds of $75,030,000.00 before expenses and an October 19, 2026 close.

Read from the first part of this long document
Oct 14
Current report 8-K Events of Oct 13
Director or officer change, or executive pay

On October 13, 2026, Alector, Inc. repriced approximately 4.05 million employee stock options to $1.87 per share from prices of $6.48 to $33.11 per share; early exercises require the original price during a retention period.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$173.47M
Trailing 12 months
Net income (TTM)
$41.41M
Trailing 12 months
Revenue growth YoY
+4,895.9%
Year over year
Operating margin
20.2%
Trailing 12 months
P / E (TTM)
6.7
Trailing earnings · reciprocal yield 15.0%
FCF yield
-43.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$138.70M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+9.6%
Year over year · more shares
Price change (1Y)
+94.6%
Trailing year
Short interest
5.6%
Latest settlement · 3.6 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +13%
above
Price vs 50-day avg +12%
above
RSI (14) 52
neutral
MACD trend Negative
52-week position 76%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +28%
trailing
6-month return +20%
trailing
YTD return +50%
this year
Relative strength +29%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +15 funds added
Insider flow Distributing
Net -$296.1K over 90 days · 100% sells
Short interest Falling
5.64% of shares out · ▼ -18.1% MoM · 3.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
138 holders — mid 3-yr range
Squeeze score 62
elevated · 0–100
Fundamentals
Weak
Revenue growth −79%
Y/Y
EPS growth −13%
Y/Y
Free cash flow $-184.1M
Valuation P/E 6.7
below peers
Balance sheet $56.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 84%
annualized · 1-yr
Max drawdown −49%
past year
ATR 9.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Oct 21, 2025
Restructuring charges · first half of 2026 $7.7M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+13% Bullish
Price vs 50-day avg
+12% Bullish
RSI (14)
52 Neutral
MACD trend
Negative Bearish
52-week position
76% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +15 funds added
Insider flow Distributing
Net -$296.1K over 90 days · 100% sells
Short interest Falling
5.64% of shares out · ▼ -18.1% MoM · 3.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
138 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $2 · 76% Range high $3
vs 200-day avg +13% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ALEC
Alector, Inc.
this stock
$347.63M +49.7% -79.1% 6.7 5.6%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
138
% held
63.8%
Net QoQ
+3.8M sh
Top holder
BVF INC/IL
Held Float
View
Held by Funds
Fund positions
129
View
Short & Settlement
Short Interest Falling
Shares short
8.4M
Days to cover
3.6d
Change
-1.9M sh
View
Short Volume
Short vol %
54%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
3.5K
Value
$6.9K
As of
Oct 21, 2026
View
Off-Exchange
Off-exchange %
39.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$296.1K
Buyers / Sellers
0 / 3
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$21.0M
Net income (FY)
$-142.9M
EPS diluted
$-1.39
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 5, 2026
This year
19

Alector licensed AL050 globally to Genentech, receiving $100 million upfront and eligibility for up to $1.17 billion in milestones. Third-quarter net income was $124.6 million, and cash, cash equivalents and investments totaled $138.7 million at September 30, 2026.

View
Proposed Sales
Value
$9.1K
Shares
3.6K
Filed
Sep 4, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Alector Reports Third Quarter 202…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
ALEC -8.1% +27.6% +19.7% +5.7% +49.7%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +0.5% +36.8% +28.9% +14.4% +48.5%
Key facts CIK 1653087 CUSIP 014442107 13F (30d) 149 filings 130 filers Visit website Investor relations